Search

Your search keyword '"Ramirez-Alvarado, Marina"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Ramirez-Alvarado, Marina" Remove constraint Author: "Ramirez-Alvarado, Marina" Database MEDLINE Remove constraint Database: MEDLINE
81 results on '"Ramirez-Alvarado, Marina"'

Search Results

1. Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage.

2. Biophysical characterization of human-cell-expressed, full-length κI O18/O8, AL-09, λ6a, and Wil immunoglobulin light chains.

3. A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis.

4. A BAK subdomain that binds mitochondrial lipids selectively and releases cytochrome C.

5. Pathologic light chain amyloidosis oligomer detection in urinary extracellular vesicles as a diagnostic tool for response and progression of disease.

6. Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation.

7. IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.

8. Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses.

9. A Proteomic Atlas of Cardiac Amyloid Plaques.

10. Scientific societies fostering inclusivity through speaker diversity in annual meeting programming: a call to action.

11. Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations.

12. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells.

13. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.

14. Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains.

15. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

16. Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

17. Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

18. Assays for Light Chain Amyloidosis Formation and Cytotoxicity.

19. MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms.

20. Immunoglobulin light chain amyloid aggregation.

21. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.

22. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients.

23. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

24. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.

25. Solid-state NMR chemical shift assignments for AL-09 V L immunoglobulin light chain fibrils.

26. Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir.

27. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.

28. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation.

29. Recruitment of human light chain proteins by synthetic fibrils is dependent on disease state and may be used to predict amyloidogenic propensity.

30. Immunoglobulin Light Chains Form an Extensive and Highly Ordered Fibril Involving the N- and C-Termini.

31. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.

32. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry.

33. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.

34. Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

35. Recruitment of Light Chains by Homologous and Heterologous Fibrils Shows Distinctive Kinetic and Conformational Specificity.

36. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

37. Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.

38. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.

39. Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.

40. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

41. Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

42. Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation.

43. Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury.

44. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.

45. Evaluation of the BH3-only protein Puma as a direct Bak activator.

46. Thermal stability threshold for amyloid formation in light chain amyloidosis.

47. Systemic amyloidoses.

48. Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes.

49. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

50. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.

Catalog

Books, media, physical & digital resources